← Eichor
Study identifier: NCT06972875 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

Condition: Prostate CA · Androgen Deprivation Therapy  ·  Sponsor: University of Vermont

PhasePhase 2
Planned participants32
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.

This description comes directly from the study's public registry record.

Talk to the study team

Steven Ades, MD, MSc  ·  802-656-2021  ·  steven.ades@med.uvm.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Vermont Medical CenterBurlington, Vermont, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06972875